IQVIA saw the highest growth of 1.99% in patent filings in May and 1.49% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of IQVIA‘s patent filings and grants. Buy the databook here.
IQVIA has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 67% filings and 75% grants. The United States(US), Japan(JP), and European Patent Office(EPO) patent Office are among the top ten patent offices where IQVIA is filings its patents. Among the top granted patent authorities, IQVIA has 75% of its grants in United States(US), 12% in Japan(JP) and 12% in European Patent Office(EPO).
International Business Machines could be the strongest competitor for IQVIA
Patents related to electronic medical record (emr) systems and healthtech lead IQVIA's portfolio
IQVIA has the highest number of patents in electronic medical record (emr) systems followed by, healthtech and data privacy. For electronic medical record (emr) systems, nearly 12% of patents were filed and 21% of patents were granted in Q2 2024.
Electronic document mgmt related patents lead IQVIA portfolio followed by databases, and data & database management
IQVIA has highest number of patents in electronic document mgmt followed by databases, data & database management, machine learning, and retail. For electronic document mgmt, nearly 11% of patents were filed and 10% of patents were granted in Q2 2024.
For comprehensive analysis of IQVIA's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.